The World Health Organisation's approval forIndia-made Covid-19 vaccine is expected to be delivered this week, sources toldnews agency ANI.
Emergency Use Listing (EUL) is a WHOprocedure through which it assesses the medicines, vaccines and devices used toaddress an outbreak classified as a ‘public health emergency of internationalconcern’. With the approval of EUL, Bharat Biotech will be able to supply itsvaccine to other countries. The Hyderabad-based company had applied to the WHOfor EUL in the second week of July.
WHO usually takes up to six weeks to decideon Emergency Use Listing (EUL) submissions.
With regard to the limited supply of vaccinesin India, there was a mismatch between the manufacturing of the first andsecond dose of the vaccine. With this approval, the vaccine will get rollout inIndia at a faster pace.
The WHO nod will allow Bharat Biotech toexport its vaccine and it will also ease international travel for people whohave been vaccinated with Covaxin.
WHO examines whether the product has beenable to eradicate the disease or prevent outbreaks and whether themanufacturing is compliant with Good Manufacturing Practices. Once thenecessary steps are taken after that the WHO approves the vaccine.
Earlier, there had been several controversiesrelated to Covaxin at the home country as well as abroad. At the beginning of itsapproval in India in January, faced allegations due to the "absence ofadequate data".
After the vaccine makers provided theirlatest data, its high price in India came on the radar as the vaccine in theprivate-market costs more than Covishield and Sputnik V. Meanwhile, Brazil hassuspended the purchase of the vaccine from Bharat Biotech following allegationsof corruption in the deal.